- $9.04m
- $18.96m
Annual balance sheet for Impact Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.072 | 0.046 | 0.002 | 0.001 | 2 |
Net Total Receivables | 0 | 0.197 | 0.016 | 0.331 | 0.184 |
Prepaid Expenses | |||||
Total Current Assets | 0.107 | 0.287 | 0.122 | 0.332 | 2.45 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | — | 0.276 | 0.287 | 0.017 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Total Assets | 48.1 | 56.4 | 46.5 | 44.6 | 20.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 1.07 | 12.6 | 10.6 | 13.1 | 9.79 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Liabilities | 10.2 | 19.8 | 16.9 | 19.4 | 16 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 37.9 | 36.6 | 29.6 | 25.2 | 4.26 |
Total Liabilities & Shareholders' Equity | 48.1 | 56.4 | 46.5 | 44.6 | 20.3 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |